Newly-approved therapy provides improved quality of life for midgut neuroendocrine tumour patients

07:25 EDT 13 Jun 2018 | ecancermedicalscience

Midgut neuroendocrine tumours are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a...

More From BioPortfolio on "Newly-approved therapy provides improved quality of life for midgut neuroendocrine tumour patients"